VERU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Veru Inc (VERU) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock lacks strong positive catalysts, has weak financial performance, and no significant trading signals. While analysts have a positive long-term outlook, the current market conditions and technical indicators do not support an immediate entry point.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 40.621, and moving averages are converging, suggesting no clear trend. The stock is trading near its support level (S1: 2.46), but there is no strong indication of a reversal or breakout.
Analysts have initiated coverage with a Buy rating and a $25 price target, citing Veru's differentiated position in obesity drug development and promising Phase IIb trials for enobosarm.
The stock has experienced a -3.52% decline in regular trading and a -1.95% drop in pre-market trading. Financial performance is weak, with a significant YoY drop in net income (-40.39%) and EPS (-57.38%). No recent news or significant insider/hedge fund trading trends to support a positive sentiment.
In Q1 2026, revenue remained stagnant at 0, with net income dropping by -40.39% YoY and EPS declining by -57.38% YoY. The company is not showing signs of financial growth.
Canaccord initiated a Buy rating with a $25 price target, highlighting Veru's potential in obesity drug development. However, the key milestones for its lead candidate are years away, with top-line data expected in 1H28.
